Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | VNN1 | O95497 | 13/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CHAT | P28329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantethine SCHEMBL19544641 | 1.00 | PTGS1 (0.56) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL59597 | 1.00 | PTGS1 (0.56) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL19358994 | 0.99 | PTGS1 (0.55) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL19359043 | 0.99 | PTGS1 (0.55) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL8416070 | 0.99 | PTGS1 (0.55) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL9112817 | 0.97 | PTGS1 (0.54) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL9115760 | 0.97 | PTGS1 (0.54) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL8416043 | 0.96 | PTGS1 (0.52) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| SCHEMBL18314794 | 0.95 | PTGS1 (0.51) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| SCHEMBL22369798 | 0.95 | PTGS1 (0.51) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375406-A1 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASE | VEROSCIENCE LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-20250269022-A1 | ASSESSING AND TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-08-28 | — | — | US | claimed |
| EP-4334718-A1 | ASSESSING AND TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2024-03-13 | — | — | EP | claimed |
| EP-3549574-B1 | COMPOSITION FOR PROMOTING HAIR GROWTH OR HAIR RESTORATION, CONTAINING NOVEL PANTETHEINE-BASED SUBSTANCE | KOREA INST OCEAN SCI & TECH (KR) | 2024-02-14 | — | — | EP | claimed |
| EP-3628640-B1 | METHODS OF MAKING A DEUTERATED OR A NON-DEUTERATED MOLECULE AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT | HUB THERAPEUTICS (US) | 2023-08-09 | — | — | EP | claimed |
| CN-116247104-A | Thin magnetic semiconductor film material epitaxial structure and preparation method | 成都海威华芯科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-115650207-B | Porous carbon material and preparation method and application thereof | 河北省科学院能源研究所 | 2023-03-21 | — | — | CN | claimed |
| CN-115650207-A | Porous carbon material and preparation method and application thereof | 河北省科学院能源研究所 | 2023-01-31 | — | — | CN | claimed |
| WO-2022236099-A1 | ASSESSING AND TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-10 | — | — | WO | claimed |
| EP-3197436-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE GI TRACT DELIVERY | VITAL BEVERAGES GLOBAL INC (VG) | 2022-03-09 | — | — | EP | claimed |
| CN-100402640-C | Process for producing lactonase and use thereof | DAIICHI FINE CHEM CO LTD (JP) | 2008-07-16 | — | — | CN | claimed |
| CN-1761742-A | Process for producing lactonase and use thereof | DAIICHI FINE CHEM CO LTD (JP) | 2006-04-19 | — | — | CN | claimed |
| CN-1121497-C | D-pantolactone hydrolase and gene encoding the same | DAIICHI FINE CHEM CO LTD (JP) | 2003-09-17 | — | — | CN | claimed |
| CN-116247104-B | Thin magnetic semiconductor film material epitaxial structure and preparation method | CHENGDU HIWAFER TECHNOLOGY Co.,Ltd. (CN) | 2026-05-29 | — | — | CN | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | THIOGENESIS THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-1635996-A | Topical skin preparation containing 4-hydroxyphenyl-alpha-D-glucopyranoside | PENTAPHARM LTD (CH) | 2005-07-06 | — | — | CN | disclosed |
| CN-1121497-C | D-pantolactone hydrolase and gene encoding the same | DAIICHI FINE CHEM CO LTD (JP) | 2003-09-17 | — | — | CN | disclosed |
| CN-1166182-A | D-pantolactone hydrolase and gene encoding the same | FUJI YAKUHIN K K K (JP) | 1997-11-26 | — | — | CN | disclosed |
| CN-1101846-A | Chinese medicine of anticoagulating and lowering blood fat for cardiovascular and cerebrovascular diseases | WANG YINKUN (CN) | 1995-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569456-B2 | Methods for the treatment of cysteamine sensitive disorders | SLC7A11, CTH, SLC19A1 | PTGS1 365/4885KCNH2 2528/4885VNN1 53/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | PTGS1 263/4885KCNH2 1639/4885VNN1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.